Curated news and analysis on clinical trials, drug approvals, and medical research.
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
Gilead Sciences reported Q1 2026 total product sales of $6.9 billion, up 5% year over year, with HIV revenue growing 10% to $5.0 billion. The company raised its full-year 2026 base business revenue guidance by $400 million to $29.4–$29.8 billion. Non-GAAP diluted EPS was $2.03, up 12%, while the company advanced its oncology and cell therapy pipeline.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
Canaccord Genuity initiated Beam Therapeutics with a buy rating and $74 price target, highlighting near-term catalysts. Beam reached an agreement with the FDA on an accelerated approval pathway for its BEAM-302 AATD therapy, which showed early clinical proof-of-concept for in vivo base editing. The company plans a BLA for risto-cel and a pivotal plan for BEAM-302 in early 2026.
Major biotech investment and M&A activity marked early 2026, including a significant stake purchase in TG Therapeutics and multiple high-value acquisitions within the RTW Biotech Opportunities portfolio. The sector showed improving capital markets and strategic deal interest following the JPMorgan Healthcare Conference.
A new cerebrospinal fluid biomarker for DOPA decarboxylase (DDC) shows strong diagnostic potential for Lewy body disorders including Parkinson's disease and dementia with Lewy bodies. Validated across multiple cohorts, CSF DDC levels were significantly elevated in these conditions with high diagnostic accuracy. The biomarker correlated with alpha-synuclein pathology but plasma levels showed no diagnostic value.
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
Long COVID patients continue to suffer as federal research funding and support programs have been dramatically scaled back, with the Office of Long COVID Research and Practice closed and NIH grants disrupted. The chronic condition affects as many as a third of COVID-19 survivors with over 200 possible symptoms, yet experts say the disease remains difficult to research amid politicization. Medical professionals warn that reduced resources undermine diagnosis, treatment, and the professional pipeline for new research.
The global growth and differentiation factors market is projected to grow at an 8.2% CAGR through 2035, driven by expanding cell therapy manufacturing. GMP-grade revenue is expected to surpass research-grade by 2030 as the industry transitions to clinical and commercial production.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Vancouver police seized over $79,000 in illicit drugs, cash, and weapons during a six-month investigation called "Project Bingo" targeting drug trafficking on the Downtown Eastside. The search uncovered fentanyl, cocaine, methamphetamine, dilaudid pills, illegal cigarettes, and a large cache of weapons. A 61-year-old man was arrested and released pending further investigation.
A case series of three Erdheim-Chester disease patients demonstrates the disease's diagnostic challenges, with one patient improving on targeted BRAF inhibition while two others died within a year. The rare histiocytosis often presents with multisystem involvement, delaying diagnosis.
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
UC Davis received a $5 million Gates Foundation grant to expand self-cloning crops to other staple foods. Congress approved continued NIH and NSF funding, maintaining similar levels to the previous year. Faculty and students emphasized federal funding's role in supporting basic research and training scientists.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
Clover Hill Dairy recalled requesón/soft ricotta cheese on June 3, 2026, over potential Listeria contamination, with products sold in New York and Virginia. Listeria causes approximately 1,250 U.S. cases annually with an 86% hospitalization rate, and poses severe risks to pregnant women including pregnancy loss and stillbirth. Health officials advise pregnant individuals to avoid raw milk products, soft cheeses, deli meats, and hot dogs.
Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.
Real-world studies show early complete response after CAR T-cell therapy predicts sustained remission in large B-cell lymphoma, while historical chemotherapy yields poor outcomes in high-risk patients. Data from registries highlight a significant event-free survival advantage for second-line axicabtagene ciloleucel versus standard-of-care salvage therapy.
A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
